Watch this short video highlighting our CellXVivo™ kits developed for the consistent differentiation and expansion of T cells subtypes, dendritic cells, B cells, cytotoxic cells, and more. Kits include buffers, cytokines and optimized protocols for easy and reproducible cell culture.
Learn More About CellXVivo™ Immune Cell Differentiation and Expansion Kits
Recorded June 15, 2018
Bio-Techne’s Go Everywhere Travel Grant Program awards $1000 USD (or equivalent) to one researcher each month to attend the meeting of their choice. This grant program allows the researcher to attend more targeted meetings in their field and provides funding to support both small and large scientific associations that promote discovery and collaboration.
The recipient of the June 2018 grant is Lucy McDermott, a PhD Student in the Nuffield Department of Clinical Neurosciences at the University of Oxford in Oxford, England.
Myeloid-derived suppressor cells (MDSCs) are a diverse population of immature myeloid cells with immunosuppressive properties that accumulate under pathological conditions including specific types of cancer and infections. Two primary subsets of human and mouse MDSCs known as granulocytic and monocytic MDSCs have been identified. These cells are of great interest as high levels of circulating MDSCs in cancer patients have been shown to correlate with clinical stage, metastatic burden, and resistance to both chemotherapy and immunotherapy. As a result, MDSCs are now recognized as a major obstacle in the treatment of cancer. Multiple strategies targeting these cells are being investigated to determine if the...
We have captured this month's most interesting, innovative, and maybe some of the strangest examples of stem cells in the news from around the world.
A whistleblower in the misconduct case at the Karolinska...
Antibodies are critical tools in the majority of research and clinical studies. However, unreliable antibodies with poor specificity or reproducibility remain a significant drain on resources across biomedical research and industry. Widespread acceptance of the need for end-user antibody validation has led to high profile initiatives and guidance (e.g. Uhlen et al, Nat. Methods 2016). Aligning to these principles, the AstraZeneca Affinity Reagent Group provides company-wide advice and scientific support in the validation of both commercial and our bespoke antibodies generated in-house. Our work feeds into activities across the drug discovery pipeline, including target identification / validation, hit-...
